Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1991 Nov 1;145(9):1107–1116.

Use of acetylsalicylic acid by physicians and in the community.

J Mahon 1, K Steel 1, B G Feagan 1, A Laupacis 1, L L Pederson 1
PMCID: PMC1335868  PMID: 1751930

Abstract

OBJECTIVE: To determine physicians' attitudes toward prescribing acetylsalicylic acid (ASA), physicians' own use of ASA and the prevalence of ASA use in the community following the trials of ASA for primary prevention of coronary heart disease. DESIGN: Random sample surveys of physicians and the general public by mail and telephone respectively and a mail survey of a selected panel of expert cardiologists and neurologists. SETTING: London, Ont., and surrounding Middlesex County. PARTICIPANTS: A total of 210 physicians (77% of eligible subjects), including family practitioners and most types of specialists, with an active medical licence and 666 English-speaking people (75% of eligible subjects) aged 18 years or more living in a household with active, listed telephone service. MAIN OUTCOME MEASURE: Long-term ASA use (at least 80 mg on alternate days for 4 or more consecutive weeks) for the treatment of atherosclerosis. MAIN RESULTS: Sampled physicians and experts agreed that long-term ASA therapy was indicated in patients with unstable angina, a transient ischemic episode or recent myocardial infarction but not for primary prevention in healthy middle-aged men and women at low risk for ischemic vascular disease. Both groups were uncertain about the role of ASA in primary prevention in asymptomatic people with risk factors for atherosclerosis. Nine (16%) of the 55 male physicians aged 50 years or more took ASA routinely for primary prevention. In the community survey almost all those who used ASA routinely were 50 years or older. The proportions of men and women in this age group who used ASA routinely for any reason were 19% (95% confidence limits [CLs] 11 and 28) and 14% (95% CLs 8 and 19) respectively; the proportions of men and women who used ASA routinely and apparently for primary prevention were 8% and 1% respectively. A total of 43% (95% CLs 30 and 57) of those with apparent ischemic vascular disease took ASA routinely. Medically unsupervised long-term ASA use for primary or secondary prevention of ischemic vascular disease was uncommon (reported by 2% of those who used the drug routinely). CONCLUSIONS: Physicians generally agree on a role for long-term ASA therapy in the secondary prevention of ischemic vascular disease. However, the prevalence of long-term ASA use in people with overt atherosclerosis in the community may be less than optimal. The role of the drug in the primary prevention of ischemic vascular disease is less accepted. Long-term ASA use in the community for primary prevention is uncommon but detectable.

Full text

PDF
1107

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaron T. H., Muttitt E. L. Reactions to acetylsalicylic acid. Can Med Assoc J. 1982 Mar 15;126(6):609–611. [PMC free article] [PubMed] [Google Scholar]
  2. Bombardier C., Tugwell P., Sinclair A., Dok C., Anderson G., Buchanan W. W. Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumatol. 1982 Sep-Oct;9(5):798–801. [PubMed] [Google Scholar]
  3. Cairns J. A., Gent M., Singer J., Finnie K. J., Froggatt G. M., Holder D. A., Jablonsky G., Kostuk W. J., Melendez L. J., Myers M. G. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985 Nov 28;313(22):1369–1375. doi: 10.1056/NEJM198511283132201. [DOI] [PubMed] [Google Scholar]
  4. Chang H. J., Bell J. R., Deroo D. B., Kirk J. W., Wasson J. H. Physician variation in anticoagulating patients with atrial fibrillation. Dartmouth Primary Care COOP Project. Arch Intern Med. 1990 Jan;150(1):83–86. [PubMed] [Google Scholar]
  5. Dalen J. E., Goldberg R. J., Gore J. M., Struckus J. Therapeutic interventions in acute myocardial infarction. Survey of the ACCP Section on Clinical Cardiology. Chest. 1984 Aug;86(2):257–262. doi: 10.1378/chest.86.2.257. [DOI] [PubMed] [Google Scholar]
  6. Folsom A. R., Iso H., Sprafka J. M., Edlavitch S. A., Luepker R. V. Use of aspirin for prevention of cardiovascular disease--1981-82 to 1985-86: the Minnesota Heart Survey. Am Heart J. 1988 Sep;116(3):827–830. doi: 10.1016/0002-8703(88)90344-4. [DOI] [PubMed] [Google Scholar]
  7. Hennekens C. H., Peto R., Hutchison G. B., Doll R. An overview of the British and American aspirin studies. N Engl J Med. 1988 Apr 7;318(14):923–924. doi: 10.1056/NEJM198804073181412. [DOI] [PubMed] [Google Scholar]
  8. Hirsh J., Salzman E. W., Harker L., Fuster V., Dalen J. E., Cairns J. A., Collins R. Aspirin and other platelet active drugs. Relationship among dose, effectiveness, and side effects. Chest. 1989 Feb;95(2 Suppl):12S–18S. [PubMed] [Google Scholar]
  9. Lasagna L. Does the public need protection from itself? Clin Ther. 1987;9(3):240–242. [PubMed] [Google Scholar]
  10. Paganini-Hill A., Chao A., Ross R. K., Henderson B. E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989 Nov 18;299(6710):1247–1250. doi: 10.1136/bmj.299.6710.1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Paganini-Hill A., Ross R. K. Reliability of recall of drug usage and other health-related information. Am J Epidemiol. 1982 Jul;116(1):114–122. doi: 10.1093/oxfordjournals.aje.a113386. [DOI] [PubMed] [Google Scholar]
  12. Peach H. Trends in self-prescribing and attitudes to self-medication. Practitioner. 1983 Oct;227(1384):1609–1615. [PubMed] [Google Scholar]
  13. Pederson L. L., Bull S. B., Ashley M. J., Lefcoe N. M. A population survey on legislative measures to restrict smoking in Ontario: 1. Design, methodology, and sample representativeness. Am J Prev Med. 1986 Nov-Dec;2(6):307–315. [PubMed] [Google Scholar]
  14. Peto R., Gray R., Collins R., Wheatley K., Hennekens C., Jamrozik K., Warlow C., Hafner B., Thompson E., Norton S. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988 Jan 30;296(6618):313–316. doi: 10.1136/bmj.296.6618.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rubin R. J., Brown D. J., Taylor J. W. Public awareness of aspirin and sources of aspirin information in a rural Iowa community. J Community Health. 1983 Summer;8(4):229–239. doi: 10.1007/BF01666776. [DOI] [PubMed] [Google Scholar]
  16. Stein C. M., Gora N. P., Macheka B. M. Self-medication in urban and rural Zimbabwean communities. Br J Clin Pharmacol. 1989 Jun;27(6):741–747. doi: 10.1111/j.1365-2125.1989.tb03435.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES